

0002007191-25-0000096-K Telix Pharmaceuticals Ltd 2025011620250116182616182616182616 0 0002007191-25-000009 6-K 3 20250116 20250117 20250116 Telix Pharmaceuticals Ltd 0002007191 2834 000000000 C3 1231 6-K 34 001-42128 25536630 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 6-K 1 illucix6k.htm CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 6-K Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the month of January, 2025 Â Commission File Number: 001-42128 Â Telix Pharmaceuticals Limited (Translation of registrantâ€™s name into English) Â 55 Flemington Road North Melbourne, Victoria 3051, Australia (Address of principal executive offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Â Form 20-F â~ Form 40-F â~ Â 1 INFORMATION CONTAINED IN THIS FORM 6-K REPORT Â On January 17, 2025, Telix Pharmaceuticals Limited (the âœCompanyâ€) filed with the Australian Securities Exchange (the âœASXâ€) an announcementÂ captioned âœIllucixÂ® Receives European Approval,â€ a copy of which is attached to this Form 6-K as Exhibit 99.1. Â Â Â 99.1 Press release â€“ January 17, 2025 Â 2 SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Â Â Â Telix Pharmaceuticals Limited Â Â Â Date: January 17, 2025 By: /s/ Genevieve Ryan Â Â Name: Genevieve Ryan Â Â Title: Company Secretary Â Â Â Â EX-99.1 2 illucixpr.htm EX-99.1 Telix Pharmaceuticals LimitedACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia Â ASX ANNOUNCEMENT Â Â IllucixÂ® Receives European Approval Â Melbourne (Australia) and Liège (Belgium) â€“ 17 January 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent IllucixÂ® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM2 as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)3Â agree that Illucix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country4. Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented,â€œWe are delighted by this positive outcome, setting the stage for a European commercial launch of Illucix. This clinically important prostate cancer imaging modality is currently recommended in international clinical practice guidelines including European Association of Urology (EAU) and European Society for Medical Oncology (ESMO).â€ PSMA-PET imaging5 represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT6 scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). European guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease7 and evaluation of BCR/biochemical persistence (BCP)8. Â About IllucixÂ®Â Telixâ€™s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11Â and marketed under the brand name IllucixÂ®), has been approved by the U.S. Food and Drug Administration (FDA)9, by the Australian Therapeutic Goods Administration (TGA)Â 10, and by Health Canada11. Â Â Â 1 Positron emission tomography. 2Â The German Federal Institute for Drugs and Medical Devices (Bundesinstitut f¼r Arzneimittel und Medizinprodukte). 3 Germany serves as the Reference Member State in the Decentralised Procedure. The other 18 Concerned Member States are Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Spain, and Sweden. 4 Regulatory approval timeframe from EEA CMSs may vary considerably. 5 Imaging of prostate-specific membrane antigen with positron emission tomography. 6 Computed tomography. 7Â EAU, ESMO. 8Â EAU. 9 Telix ASX disclosure 20 December 2021. 10 Telix ASX disclosure 2 November 2021. 11 Telix ASX disclosure 14 October 2022. Â Â Page 1 In Europe, Illucix, after radiolabelling with gallium-68, will be indicated for detection of PSMA-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: â— Primary staging of patients with high-risk PCa prior to primary curative therapy â— Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy â— Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated. Â About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn. Â Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com Â This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. Â To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as âœmayâ€, âœexpectâ€, âœintendâ€, âœplanâ€, âœestimateâ€, âœanticipateâ€, âœbelieveâ€, âœoutlookâ€, âœforecastâ€ and âœguidanceâ€, or the negative of

these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telixâ€™s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telixâ€™s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telixâ€™s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telixâ€™s preclinical and clinical trials, and Telixâ€™s research and development programs; Telixâ€™s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings Â Â Page 2 and approvals for Telixâ€™s product candidates, manufacturing activities and product marketing activities; Telixâ€™s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telixâ€™s product candidates, if or when they have been approved; Telixâ€™s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telixâ€™s expenses, future revenues and capital requirements; Telixâ€™s financial performance; developments relating to Telixâ€™s competitors and industry; and the pricing and reimbursement of Telixâ€™s product candidates, if and after they have been approved. Telixâ€™s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Â©2025 Telix Pharmaceuticals Limited. The Telix PharmaceuticalsÂ® and IlluccixÂ® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates â€” all rights reserved. Â Â Â Page 3 GRAPHIC 3 image1.gif GRAPHIC begin 644 image1.gif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m28Y3PB4P: M31"/.\$46.@Y'-Z0B#[>8Q1IRL8A> [& (5Q_A%&)(QB8(KHQ 72!@SJE+ .-\$C-M>I8XG7G18XJ4T:W2A&Q;4(A6\,(QC)V,=" #C*0A#RD(?FH2*C)D22)9.3U MZ +^1DH2@(_L#A3K^!@>M)EMLE4)/UZSG_L,73D?XL]Y%@XLTM2G0D4Y4.6<"Lj7 M4',G-*TH\$YE#TI9N[\$(!#>I"2^K2H@HUHT@E.KA@>A"C#I5B75%I3Z6Z3j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i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j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

M.T??NWE)@4 T;X"[*8H\9P\$AKXQI;WDEG]L"!CP.X\$(C/XJT)!4;]9A(.,
MR[_j6Z,,\$636:KP@S*8'&8'IVV41#IK4:Y5<*Y@,;, &M*Z I _,*6&\, '1)WR MRT%H@:0:O,%CJF>*X(5<(B,< "K!)"63 M,
<6X]G^Z&U1"G+#[Z[T\K)Z96:8 +&W*-%%\$G+A&O(^1D\1\A;YN; ,4[HYAI MP<8@=\+>.L\$ %190?\$0^B,<[?
*AD*JMEBHG,Q!-G[+1IC'JM _T/'6jC 3?S& MN,BS=CS#C^R/ O)Z3*G>\Q"E#RW7KR0UQK*.TH9A[RQYOMLR,/(EI'%
<+S) M116->*RLR%K),LP4K?PY1,?*&16&L5P[X2&A/BS&PBS(.NJCQ\$D9(6RSI_Q6 MWJ/*!7?
+M,S\$R>NDRS%KQQQ>=K+GHN,V@R[D;>IOWRCP4S,C3K,V[JQDY, M_)K(\$SD SAP;UPS-L3RV\ERYUBS-
[#H4W9Q(\U;/4Q,62%N:WB%K@5S.Y)RO M&FJZDJ'.Y#0"ER1'[ZR=F\I-S-K]K&_@S+NBS+/3'1_(9^SQ-8&'!VS&7YBS*
M/7K.I6R7D<'0DFK\$751.\$>T< 1W/-/^ -59X1TS^!TQ%1TZ7ZHA _=1R&]M]=Q MT"6]H2>=TI2ZT"F=O5D[4#H-
<1Q]I>U6S:U)U6G4O+H1U5T8TM'W'\$1]U&J* MU,<+&8<.,)S9EBCU7Z\$UFS='12M*-&*TF'-
T@P=&0,LCMK3UGJ]UWS=(CQ- M'&)-UVS;20K-U!74UXB=V(K-(H%KK+@AV)]V _SM(M=V99]V4?FSR(#&Y'=
MV?_9\$QU]#%2+V:1=VJ;,)UHM&H&-U# '1AX&QSJ<=V[(JVVNBUEHF2SJO-TBX! M33V]J[3]V\ =W&C2V#QMBH21VW?
=\$L3MK#Z1U,+]W- =W5%2W"8%%YZMSJC+ MW\$8APM+=W=[_=U.M;)N!7(C<:/, :3@G=[JO=[P9MM(N,4G<=UKR]
[T7= V M/5#477-16-X9>] _^ _=\ _DN.O'.P*M _H'. (GN * _D@ _O9P%SM^VNN 2/N\$4 M _DCBS7@K >T6N\$GDDSC<VJ].
&WJ8?N(HGN+E9-LMH>\$9]N(P'N,R M3EEUVN(E;IPW\$3PSON,WN,'#'\NP=Q,88^7N1&?N2D+=\1Q7-(WN1. _N1H
MW=GI9\$907N56?N6=5 _N4P5==@/N9D7N; /;YFGN9JON;>7;QL M _N9P'N>Q3=ER7N=V?N=V;-
XON=>WN<.%K5^'NB'\N@-U="?\$NB(_Y[H%M32 MBM[HCO[HR1.DD#][IE%][ID9.KEI[IFK]IG-[IGO[IH!][JHC[J]I%][JIG[J]
[J MJK]J-K-JE"5"KA[KLC[K18),M'[KN][K*A)%NM[KOO[K#0)8P#[LQ%[LS0(C MQI[LRK[L2BL]S/[LT!
[MOE\$YTE[MUG[MI5%RV+[MW-[M1@\$] MY'[NZ][N9Q%"ZM[N[O[N5%'#\ [O]-[N<6L[>%3O^K[ORPYJF/8IQL3O C_P
MM^YIG39R%47P"K PJF[PE/9D6L7P\$C QIN[O3\$=<%) _Q&D P%;;Q'O Q[UYJ M(# R). MO%?
R*) RS"ZO.Q82 _N[PH;:R,O\ _PG3&G:T;X8-R^& \SH?9C3 _M/T /*+8^/N#W,CQ _]#V/]\$H?
=4'?]\$Z _ZPXS0BP/ZRBY]%;?)%A _]9V/]\$S? M]?TA["(Y]3]BUEE?JEIO]FC _%Z _JFQO'<&5\$P8?&-ZXVV=?]VE _JW;/:6V _
M]WQ/&[D#\$WEOSS#AC39_U7A _^(&?^ (AOM7W?^ (XO]?1B]G)<;80 _(&2L^:K/^:R _^*# _^K /%KBS,JK[HUN?
BE/ %T].VU#U&-% [L# -0TO[PW _WR M' _T/ _V [C/7?]ZS[#W? _#[ODD @4O@0((%#1Y\$F%#A0H8-'3Z\$./!"A(D5
M*5ZTF!'C1HT=.7[T&!+DR(D139Y\$F5+E2H8\$3KB\$^5)F3]HS;=;\$>5-G3IX[M?78\$*I/E4*)%C1Y%FE3IR9]-
@SYU&A7]5*E5]5ZUFA7K5]U=N7[U&A;L6+\$G MEIY%FU;M6K9MW;Z%Z[8L6;HZX]
[%BZONKUE1\ _X%'%CP8,*%#1]&')CD8I&- M,2:&O)+Q9,>5*5^V?*"RYK9V/?>MRUGT:-
(09 _^G[KU:M6M6;]V'1OV _^O2 MM6W?QIU[[6S964#YAT][F _BQ8T?1YY<^4# ,S3,OCYS9^73IU4EJAIY=8&_A
MM+5 _!]=?QY/7GP[=V_AR]PO?J<\5'Q\ 7 _G[^ ?W _\2Z 2\; MC2S"J\$-P0 4)!-"X !X\$JD\$)!8.P0OHLQ!"#3/DL*
<)/P0QQ*(Z?!!\$C?< M2D055V2QQ=P6A\$ _DP[C]T8;\$!0Q(Q=S0!""7]/SLT=W MC!1/2RO%)%(.)^6T4Z,TEP76*UV')?
97[^)#(=@IB66VV3^G0HI669N=M5II#W46+V.I MS+; ;]5%EQQ->RV7\$#[':ZU]%ZYU _GJMV F!PX+P(" _-
+AAAX]#3=Y[[W67HM;?7BWA6 *_J-/T889)\$Y M[KAD"4/NRL21QS*Y99<1.TVIB?
&M>&;JWYJ]63%S;GGME#VS6>AA_X.Z%Q; M7/DGHI=F&BF&D[IYXF[_+Z9ZN@NNGJBJYM>B6>NOX[(:*K
)KMLR,2NZDI> MS6[:;81*7*K]6<[\]H=*;2KUUYUYN%ZS* M+S97\N8PYQSWSG7/'&^]?6]]X31??
WAU#XE' _G3C^TR^>>?7)%5VVVF^>;;\ M*L2;(MXSWS[WWW?W/7SQ\TY]X>?=7;Z^_PL,/7VSUG?(_9K@I[_DX-%:W;]
M-X,[+BZSYUX O3= \F.; ^-#8 +%ASK1V6]8K.) Y4"P3:ECH)"D2!ADI:H M_X)M,#BD 9A:IE)! M'J;K:SA\GPX-TT/5.
(N(QRK0MM@RPJ]K]!7*#X9SV!,A"*F[/@#+\$8A:UN+7& M^4J(CP*B _8XXQORX+
(Q?/!L98<6I]JDQ7K8QUO686+F)]"\Q59SB"L7WPBWV MT8]8.*ZT&BG,UK0C8>44KX*.4C^(9)E='+D&ZO70"CJCFX
*6)N]!C*_ [1 MDY]\$9>\$R4CH7=!P0(SD)BU2%("I6L U[J\$Z8;\T'&DK?4R+LX64!0]M*7 MO73;%09)%8R39;#-D-
D1D3E:W'7,LVH3:>#IF&O&GAJ29X_3R]4MN=M.;
MY#.,J(9Y,&CF4&CEI";0_E1,CIEI<>ARG[@Z93D>%\$WN,1G+G7Y37[VTX]D
M\$^Y#0EO#P(R9)&\$#BV9SFQS%:4Z7]JF0KFBDL&LI M!W]F4MBXZ*?
[01M+B4J3S2S5I>Z9:7QJ>M&2[#.G5 _6GT'C:TX5"L%Q!C29\
M8.I4\$1W5/L9KJ%.9ZD2P#N]LX0+05&UZ4ZS6M9LO4Q9759K28:E5HE52Z_WX M*MA4\$M*OYE3+6%'93OR!2*_ 5(U
<11+,+C8U;*_ +E6]0H@LSZKK:@Z]'Z M"Q* _NJP+SG*:2<\$UQ8]UJ*<>2);+CM;+2X@? [+ZV89ZU5E.O1=@WW/(:-;
M3DZ=UJT/46V(6+LDUT(6.X*)4UQH.UO;BJ^ZX;-MP2ZEV]TBLU-++=DR28O. MKGJWMVH=7D\$FB\,6K3=V6&KN:
[6UIQ-.JY07]1U^_Z;?J _&7I(WE+E+)&ZB8 MD@ZA,AWPKA)LJ[:6=\$G+I9-S;99"/&I-7T@]C'VWR-\(<-C#X_MP9+,%X [M:
<%UHB;8C]D=X4+UQ_0R+F\!N]U'23A&%-YD"Y^KE@YQ1L/[!7&0K2MD[!(9 M>'VU _U2)!0S<,KW2;>F;Z(N[Z[Y\Q?
B(:4VRJ>)[MSQV6<>?(\$N>B)/3\$!=Y MR&WI:N MGRSSF&M&L:#4#>=&;C07)W6I]+[9Q7&>
<9[;MCP[8UI=GM:NE=_T71H[*V]! M1G67.^G(C,(PT9)F=*QA/>O^&IG6'8;T=0D,+ \$N;&-0_\$G6P]^Q,!VEZR0KM
MF;"U+9>N\Z;],RH*;MV59'&M>/KC6VKVWMCV=[V]<-%Z3KE-M>7QK96%+V ML-
,JG.*TN#WN+NBZNP/49A>,RQI)]9,C[[/:VY:UM _\#0O!;A]O;]OJ]V MKL%I)H;:S28;N?>6 M77)OZO+?3R:XOCK-
==ZKF\,YXS7G>=B)3MF?"WVX.6 _V\$EF ML(;W#(]+9SI6H;,7Z:I97.BQ=WR _2Y->MP2=:KKW? \WSO@_SYZT05]ZTA>?
^,?W^W]0GWK5 MTQZEKH=^ZXLM^*;UV?1;TVE=;7\K^W>\H>);643+OR6(J _\QD? _^;..:S
MO_I4SA+V;1 _V[#2^ _H_WN/S-PV#*L[W[<2\A^A@,\DN _E0 _T3 TL.YW'. M!30\5NL!F0X _N^!S0Z_3.A\
(3Q_F_DB_,X1"-!!3! R3!\$<2ZN8LJ"60 _MZXN_%%!);&_*,^5)D_83*MP>/ #M0P=S'!O3!'D0_X]@X.-&^%WR _UJ
M"#1"D: + H)O\XJ!K_\$3&QP='=Q![05*4Q?O[1FD10CTJQ&QQ1)
MQ2)Y'E24(:A,M')IQ63D0DR*Q5O\$ LURL\$HHKF[1YH#W410L\$N]U<"D/DPWU9 M'U0T1FX#,61T164\ P+L ' &? \0VM*
(XSF8@Q%4'LM%U<\$>-B1O3:.E-TGI(+ MQX\$+1[HQQW),/[G8&'4LKTZD-^FS%0\$\$(W94#GFL0+)*C :KQ _X^D9^ZD>
[M\$]>[&Y_2*"K ",B0 _#N"U\$>#]\$1Z+!8,A E*E!"N,RQH?\$B'#\$1NO\$-M)"Q[MNL@-6SF4X\F,9+F>9+,[\$0 _\$B1-
#VW8\$3W"N4'#\$U=,H+:4<67\$>8M*;/_ M4@Y[7\$H\A!^ _Y.J]-]_W\$F#FY&A% RC+,3YL%\$:F
M1\$&C,@/^O\$F&VD>@[_J]P[N-9+3/*PP05]2SK\$TK""U\$2]\$:W=\$NA\BF9 M1_ZVY R*\$S\$]Y"R1V4J _\$K
]\$P" _+Q:BXQ,M(VBA\$22#% %C\$;)=?)'=\$SK M"1"*M#C%&]JP>C#&GMP.1^&^[_R?++/_T'R_X)RZHR06PQ3!M_
]U<0RNMPI MUW1..BPKUIP^YDPBN[02K/2/#1K&S^3-P P^X?S.OJNUOF,6XS0_Q"0VY5PG MZ>R9UW3-U:3-
Z93+Z@R]4@E&49Q%=\$D>GP1/T S/XO/"C3-\NP4%'/3I%- M%7//8>NS^)Q-
ZAP,W(0Q"96G9\$I\$C03.#/6[\1S0#BO.#E5 Y,RD SV5! VD M!1VC56)/XC!1I-@S@XDQ _[A/2DL=#?
5/#ITY\$#6^#S5/\$4/*TR#19FE1YT%1 M8+KUG-%UW15UW6UH04-\$6D]RTL]07:EUWJUWUW% MU\))4^@DCG"E0RS-
UX 5V(\$EV(*MO7TU4+?P5RTTV(9UV(>%V(CMU\B'='- M6])@E-B,U=B-Y=B.54N\$#:NV@-J=F? !5KX2;><'=F1#-
JC1=JD5=JE'1WV(M]79=JH ME=JII=JJ]9MT?%II]1(?LMJN]=JO!=NP!38:N0MX'5=)\$=NT5=NU9=NVE=5*
M#8R8<=NYI=NZM=N[M1-"18P]#2*)=N !=S %=\$S^H-!-=S#1=\$S55P!-X27>XC7>DPV\
MXU7>Y67>YG7>YX7>Z)7>Z:7>ZK7>Z\7>[-7>]>7>[O7>[P7?!\?7\27?C7? M\T7?]%7?][67?][G7?][X7?^)7?
^1U;@!&;#&@;A\$];A M^+6,\$3;A\$T;A[\6,%&;A%G;AYJV.%Y;A&:9AVYV.&L;A'-9ASU60'?;A'P9B
MP\61(";B(C;BM+61(U;B);BHQ63)H;B*)9BD^62*;B*9B@<68+.;B+O;B
M;*65+Q;C,29C5IV6 S)&XS168S^5FC5V5S>&8V=LXSBFXSJV8*;ESO6XSWF MXYZ*FCX&Y\$ 69/LAH4\$VY\$-
&Y,]IHD1FY\$9VY*:1FT>6Y\$FF9%PDG#NRFTK6 MY\$WFX-XC.S"1G\$X6Y5\$F9?
2D.U" ^I5)6Y55F99:H5KRXI%:6Y5FFY4+D#<"8 MHUK6Y5U6Y5>^B[GBY6 69D]N.,&0KV%&YF1.9%M%96!6YF>&9D-

6E,6WVYF_ ^9FZV7W FYW)69G&N*G-6YW6F970>9W:&YWCN9'=.
M9WVFWYWMN9'I^9WSFYW[F8WWNWRT%"W\FZ()F8(#NDA E4X-FZ(;NUH!&E?M
MTQ%3'A>'MNB+YE0"CFB\$AFBVD!^,^!NF05L<%(A6) @BX<#"15NF5MC20V&B3
MUB>|IE"6INF:MI\,/A6.YHBXL#V;JNF?1IT/-A6=)FD1?4J@1NJ DAN3)*&FB MUFB4?DZEENJI-A@&*1687HR[H-
A\$|>JN]NI2<0Y7XHG1<&H)YFF6Y>J05NNU
MMI('DP#412L;HSYV NK%68^N[QFL]Z>&X90W#D&NAIE:T'IN\)'NS"UHX\$"0Q?
M)LJ_ GFMB%6S),^S(EFP%'N*8+W59NVSJ&+ +[FO\$, &W'X.O4]KG6QNW;NNZ:8H;YNJU ZM
M(NWN\I.J.:?4):.N%0\W9OELCY\&YNIE83M9M8Z,90#-M?N#R?@2;H/J:R M^7Z.0)\$X1J]7N U>C]#72-
/614GY=7/1T&D6<:EEW[Q]8XW)U-'(I?R(B=>'5].M%IE?+(5 M'Q^0#5?2<9KR,*?RWC6: ^O\C7.)T/ER-LFW47?[\1S])6-
] % ?<]7]]"GKQ4FN*9CYH\|B]"YG"1//5&7]5%- MW8]6&'>49+D*0),D=3UW=,*A=,*;]6"SQN75\$Y44T9^K*T5LQKQ=
<0>TZ2Z M.4"G=CD770<%(?I[9-=*[*\ (M]P41)3;MM6JW=R4\$7>:-CW7_XNTVB BT3;M= C N(=POYG#7L-7-
7^"L+W3,? M(O)MQ^)I+@J)ABXDDNV"WVO#8?AZ7 B.7YF&=_TPG4KCFZB .A=3Q'FQOAP M/W@+3?
A[A E!S >0AY21;V*IB!;3;I9GOY/09F;\ _B@IT+-=?C:M/0E3G23 MAVE36 E?=QR7+S>AE_J%]MRB5W6:-&+
(+@JB9GJ>%VWET<[4B FQU\V9QW;; M %8?9N:Y J]=WJ# /YV5:D'RI N/VURK%WE)S I/9ON SA:O[WG4\$9@OG/K"
M+P^0/WL>P?<@]@R9R>R ? N,IZ\$CW\2ZMWP+0?POM<1QW_O8SGG3AGS _WK! M _W@|O?S3GXO,G\&?"
8BOFRD4&_*B7RX9Z'*CEJ\OWG_FJ]*D)Z7H?Y]Y9] MT4]B0RI[I<5]C]^W\!:)4[/SX_]BIE]R8 [XC_.Y&=^W?!.EX1B]7]M
2^7 MZ+^=A";^%0=:ZS]B\]>.'N%B("Q&&"B0X,\$!)A -Q.6SHV"\$B!|(G4JQH\2+&C|HWNWKS\MWKMRJ)"MH)Q_XM#-
@PXL.*\$]\U2->@P<&2)WJ]:QGN9IOA MUXOWFOX] /CRY].GR=ZWTN;ZE_/76WJ]P'N-R!U>\$57X(\$1_)?=?>UQM2"\$
M\$?;4((4.KB0AAAEJN&%2%7IH(4DJJ]&/'@J)(9 J&KGBD\$GB="23#RHY7Y%1QO8DE55:>25N
M33JX%/^7=;H%V=!4N4EF1\CAIFI3>>!"F/98*%E_@LJ:E:BK+
(Z8):.J@K5/E^E:TU8XU\;!Q6;M;MMAZ*]*V37WK9[@;=GLN M:-NBNZY;F[\$KVE+&+NIEJ^=6):]B: ^J[.]K-/OLOP
N5*^Z[F0U\| %&CHHJP M:04[K/!6#,\ \$L:,2\$ _DPQC"QFC"2+K9L5&^SHLO@62M.R/_R8#MFRS+_SH; M<,
6]T0Q4C+;/#(>]Z,5LXJ]TQS4SJ[YK&?0" \I*J='GQSFT\$,U-3+4+8JU M-,IEKEPIUI?V"S/771==D](H?3VVT&\$?
2;:T3:MMMM-%LWTVVO2MC2Z?XBL>=MXJ.]0XY)7K*K'EGTI^
M:N9Y8DDYKZ99#FG??"]G5;9K[85LUOP2 C+BL\CE FXG[(!K_.0PVMY&O!5FUXZ<561*EESK[>>K.&S: ^JU\1&JW;W-
RH\ 'M_D7B'W\^Q+::GR[Y]*%M(GO XE: _-C/7]_J%R*0?@>XL_/?Z<*""J48R' 7 M.^&S8#? %7(-
@; >KH+4N6*KVR;"&DP)H6PX&QBZ3X=3BI /QY<:R'D.A! ^\$ M4;7^9T(6,K&)B2,?XW@8K2""I'LWO"
(5(WBG+Y%BCW\$(HCJ\|UL,9W@C\$B M&H]CKJ6R,7M.?./L: &W+[*BRRIW1CS:\$>@86F/8HN/JPKEQZY\<9!\$:8T9
M)Y/&1>YE6X2#(R0C]2GP19&.H#\$DMM" FQTUB\$BA5ZJ1\QB4G3O.*)T42FWR MQK\ C,G(QUO]2H@I5*E9RHZ28;-
DTDC9MJ+ILI>G;\$F20 E(M5WIEU6TCB A M99L.>H:5S@QAM3)%RVE24V"X,QLN<*1=W/,9J\$*%;%TFI.?
JY*5/T,TS,PE*: S7\$T _W@; M5;+FG0Y53#SI*5%)U@Z; ^-RB03TFO(QRU)PBTf=ZQ)>|CAZ3>0EM'#K99IM6
M/A1,:YPH3.OIN+E=%*.&!A)3WI*#8\$4/1 44DXOYRZ=SJF2MV\$14NT2KI@R ME8F.NV5-V]336.DTJ-Z4T%3-(T,?
6;6+@JFJ1K.DTMTDM:P"B6C_4].Z;/19 M-*16RBJGN@JGM2*P"JN]#+JG=B>(0/6KR8C:'-R1[
MK/9LH9VM+Y] %B^5=MHG45;JKI5LAFKKT]2.SIIGMY] %V% _^JN=)7:XS_6C(\KT'!:M;4WA2T5E23=I;AVN5"%
MCW632ILP%DN[]H66Q=[KW;TRET^1->XOSU/Z^&7:
M *!R7 _OFU[3])>JYZW;20G%4] _TU+S^K [3>WBDW;EEL(-3C!?*C"HJ\$]8N MPRQ]81,->\$B.I:|YIA" ^98Q
G>R('1.S0,-5B^?667BU\|6P*=|8EJO&) MZAJN'E\RD4=)(!OC)\$?"YEB&BKR== \$RK20KV;_7+ "31V1E@%Z58>"M\H<5
M _8VC1@B01:C?C,\$9J1F%F, *G-AP]7D-'TSN4L[IU]'.78=MFY=ZHS+J K MH>Z*.;JAMLJWK +H0\$Q\1S83>T)K-94S\$M
ML&Q.K=&2!:=;G>I@DG2FI=9-J(CMZ\$='L"(QO6)5%SL4N%8V2I]407L"G5 M'BW7Q]XUACN'Q\ _L'AO;'O9V/E==X
P_.DG+G=@H#+FLT [IM1NFK5Y.NP2 MY;1XOU[HO'7.:%,5>];T+K>2T/W9Z\$1W5FQI=Q.E 2R%:VH!<:UVO"\&;C7W
M&GS5"KF&91SC>&8,OI!D#X0HPM]Y2RG3[GJVT&7IPV M4';9K'>>N MYK77^=1SOOR9=[5#7>X8@CD#',W
MWWK/KG3W0(=%.'V'Y0E[: 99]M'IC&^NY8\$X=1[>FX.I X[CK85Y;|5\X(2 M^>=1Z/>M\$22[:3W\PA\$O_.
3WYI=3_OI&_JZH\V^ ^78?(4)C#_OEQ]#Y]JK[MD&-5Y-Q:[Y'&C];H:4DED"1B.TIH(!-H)=(2R(')H/MUV_F130LV
M2*B<(*N,3/?EGZ;(4A/YWO;XWP *8 \$&H!\$R_QP2%F\$2+EV4+1X*UMRI%5H- MNN 4[M]IP-
_Dj:#.4"\$%O=O/(\$S8]1T/>F D>\$ (N 2%E[AL1GR:'Y12&' M5"\$7RB\$WH086MM),^MH<"E6LX& T 44'ZAX9NI&[B6#
"&\$1#J]\$1*J(BI] \$C M*B\$DEN"DY9D;+J =T=@>TN\$#NEX>EL<=GIDFULRV:&"X^~P8"J++I)49MMLC M&J
KJJ\$|BIJG52*(P:&&9"(NJA\,=J*^V6+QS.'!D&*Y-,8I?J /+IFU(. (K M,F(B-N,KMB(L1B,T3N.TK9T?TB*!|6*\$Y"
(W]MLN^J(G;J\$FA*:*F9[\$B"\$9 M#B+O;9,S1O _B&D+(B6%CL9@ (76C/O;3-U9@+?IC]X3B"XZB.5H,
M*AKC&2*.MW+;CIC-#)C/\$:D-,HC/\$ZDM%VD&CK6ID9.EUP:IL9IH^I)IFNN&AZ"8R]"93V
M9.0%)68B#EUM)DTBCDV&YE8F(6D>IVF294&JID>RIC6^)G1*61:6I6V<9--%
MIW8\('\$O63F].4UIO8C8OY)6B.)S4BIWF:GIZ\W4QIW+*YN-AIVTB9FS29G02
M)|+\$YPI%2CWR3G>2GEG0C:9U)GD6)X&>IX&BYVE2(,VPYV"Z6P"/)X3VTOM! M9G52J]#9%J
WZ5V[&37_ZY[6DCE@.*""^Y8&6*(F)V\<\$(-.8EM2W\$ZM*.XY M9W.ZYZUA*/S47FKR9X="\$N
AC _VJ[@.J(D.Z8E* YMNO!",WJ.,/N?)2DF M4F:D4J]3@1]7]BFG;J]M?F6,?&JISMVIOF&O[JH,BJJ;RF<&/FK'
M1_J&UBFLL"TU*]SWNJ?DN2@ BNOIFI8DBJUBMB\$=+2NS
MVHH!/BNZ0BNN=@8Y96NU;O^KQ&&KNQ+FFWX;O.K*V^90RZ!89V,Z;NY^4\ 'U.,N%K5O!
[D,2H;/1+NW*FMKB+MNB M+E?I8M 0CZII[]QJ[WE(IE- FK8B;50I[Q.%BO-JKAJ.7?1*[_ 3J;L36().E MB)P
K^ATZX1VK52P[N.RTW!1JC(^9*R<;|U&1>>P\|. "KA5(;QZ9R.;N4Y M,&^
[UAX+TCB[&F1[[],9ZV<,765/C]+PVS*Z+06@>CZP>O9PB'K.*RFN&*ZVT_ZK[MB_5^FH+LQ@% MVROR)B\&3]+-
&@D.HR_- [K" ^J K])VN]EB20,+ZB0T"]5IGJ;2?"NO'#0|O#K M3A@- R!\$ O!O[@]8Y+ #
!MT58W\$6BW&,YBMP".X(4^P1,W\$1WZ_Q;R/,MTQ&S M_*K%.3]M.B/-J=N-8?/,S_SY-*S-
1^T+E]SZJ]S6*/|AJB.'OS58)S7Q(H M7N*|B7,2.H%8-G0;?=-,=E0NNQU.%Q_*T1R/N0B=Q/O|. ^ H<'TH(0T
MP3Z%P95TW9YTC:9T?)JT/#]P47^G1+ ,PJY7' ^T71K?Q4YLRD%*C >GT8/*T MG/KT3Q\UPKPSA!KT+!MQ6\, _F:(Z,ZT
WG7Z-UT*X**56,D 8.H5KU M4"]F3(\URM8U59PUOB(-KON^\$IU1HNS8;,U1^ _I 19*0/MI7/OH7-,U5P?- M7:??
M?' _=4MC]D O]?OBLPB#|(->%V)/-4[?R5N_,@-'=CPS-.]X]2]+|V03
M,FM_:%GO;FUOK_Q<|#:VG'26,?)VI3B&H+L5Y3766[W5]S M\B;WL6" |M@GC+7=<41K'U&@K=F@62D@W6X4D]Y-
I<6LWM\>%KDO;<'HC&'6C MW6TODP(-F]JO-&G7]ZP"]XDRMB/G+JR(JWBOMQ6Y]N@DL&:K=X'Q!(O+DQ'
M]S8GK23]-FD'=Y%Z=W'7[F;-B']_,7E[D8"#3!UM>!@?.(HD=7B1N" _E,(? MH6^O>#Q*N+,22H5W[&:'1H8?
[FP36H=#=K6 L8"-H* M^SQ_Q4PCQ\$N')\$HH 3T4IU;B-.S0VFC?V(C2 BPJ(>X1?NTU[-RZ1>Q&+<[>0WO?
MPCCM#G>'C:4H[>(6QN5HY1;7KD2R[G7=KG,%)MZUI#%'GF8]ZF2-RV,GS-X M+ ^2:% I^!&A)]JB/PXI55"?
W^1;SZ.@4+&3.|FB7WK\$C1JF;SJGXXZ\$%I"8 M[_+QSB:6PGZJB_I=KJJ&V9/K]JKO[HE03?9]/JD&W=._> "@GQ.L[SJO]
[JO M_I&I1= (GFMHZW>I6M?XQ"P+SNS[NS]/MM2_?7^HJF^VZ+#+Z0KNV;SNW M=[NW-Z@-*0YQ%CLR!]|S?
CNZI[NZK [NRMW,Q<-N? MH*|SN]>[O=|ON=| M0R^WJES[8Y]P1||' _XD]3[BR<|.TW&(R.IQ\$||Q5>|Q=^M
MIB]5PPN[4+?P77JQ8>|R(|R5,|*(^>*O|N|IOWS6FAJR;|S,>|S*N[G5_)
MQD=|I<JDEX;IS/>|S_||T,ZGM_ZS;M|SI,16YQGT"]|TS>]TV>X]=|RLN[M; >D|0)/FTV>JUF\|UQNP @_)U".

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|##% 0E<["X#W9QJJOKHHX^F]P],4,()*:S0P@LQS%###3D< M+T\$\$.:N.P1&WB^E#H3I,4<4566S1Q1=AC/]1QAE7/!\$^ ^4C,|2L3032*QA^! M#%+((8DLTL@CD4S2K - =TM')RV"R]2@EJ:S2RBNQS%+++;GLDLH&G(Q*)BF1 M|M+,,],%4|TUV6S3S3?U E-.KAXDDP X|W4TX,DK>_ 344DMU=1344U5U4T" MK6S55V&-5=99.:W55@M#G>S677GMU==? @0U6V,%RC6S88Y%-5MEEF6W6V89: MW>K9::FMUMIKL>_ '-MTE)]>W_U]]_ 0Y88'>=-' C@@@Q%.6.&%7|V1X82122[9Y.%V.UGEE5ENV>67Z>[9YY^!7GFLH(DNVNBCD?YWQZ29;MKIIZ%^UJNHJ: [:Z]NQ+E7,K+GNVNN0 MP0Y;[+)'>MOLL]%.6^VUV6[:;?ACEONN>FNV^Z[\ <||]!#UWTT4DOW?33 M44]=]=59;]WUUV&/7?;9:._ =]MMQK_ ""W+OW???@<]OJVZ#+][XXY%'_ VYW MWI-OWOGGH0=M^0B8C] [ZZ['/7][E=]=>^ ^ !#W\FZH?O7OSST4]??8RX'W]] M]^&/_ X+R*?/?GQSU]_Z-MO?_ 1A W)6/@-43X \$1F\$#2]<]_ "G3@ R%H MN>E-T'T1M. %,4@X!O8O@QWTX ?K5C|13A"\$33A">>V00:BD(4M=. '3[%? M\$;Z0AC6T[U]T9! W&4I1CO(YEKPd*5&92E7ZYI./#*(!5QE+6^Z3GY*4IR7[&5"! [C&?W(3C0!&:T#3^\$Z *=>A#][A.@_ H2HA6U M:!:9:DA\$7I2C'76A1\$%.4%AZE*0EO6!&36E2E:[T@1,-J3Y9&E.9Z]^0*#WE M3'&:T0-X 0]!8I/>QK_ %) ^X5*2? U.E1D=HWH"Z5*\$P%R@!R8E-;)I6J596; M4X/ZTZ9N]=7B7H_JXZ5K&/#ZEFYFM430)4F4IUJ6>\$.UZRE%:U:M:M: MVQI6O7Y1KGWU:]N6E>UUG4F;GWK7Q&6))EK%TE4E1P?K2Y2F6LI6=&5TQ M&JC,GB FABVF94\$;6I,-=K.-U6I, (+M7HXJ6M:W-6&EAJUF@=-:SAW7M;7&[M,-.25K8]?6QD4RO9W Z7N +K[6Z=NLS:FG*CQ77N<^D56]Y.=WS M:Y+H9M= M[:;+I]>5+F>5NUS;;I>|Y7T6][K=7=Z9[5J^+]+ 'SQF]]G M_WGW3CJ1['_9JU|/# B']JTF@1&_ M., <]]O&K:|SD;OZ8R\$4NU8YY;&0E+QE20D8Q<)D<92DK"LGRG/*5L;PG)]?X MEUGVI?55&4KIX2 \ VN4,& <9C4;9|MM]])*SEQF],IVS76.L%BY(^8QH|3, MQJJ* !OJ&\$=TP9Z!_ 3F=9TJEFM:EQ_ .M:] MKF@42?WD1 =W);DV]]J1O6NT2MK7S;9G)PW=G%K_ \$J'5K:NL>UG5SN;V^)\ M8K'" +6Q%P_ G:ULYVLL_ =;75\$XO=F;:MH8- N<|];WO5N[+;7G>]SPC%.28#WV]3_ ?CJ M*6YPBQ>F.SWJ7/=Z;ZD>_ M]ATV- .J,+AWB|NQ[TM\$;=VV+ _=SL+4^SNK'<|'Y1^]79?G>:OYW&'SEWQJ<_ MDT[WQ.S4;@G>UYXXQ&.V[XU7((- QHFK_ SIWRUW6)XO6>=|T3W/&=UY_ +ZT3R MJ!;_ ^[";9_ (SCWET>Y[UZ@MK35Q=;IQ4WN.1#3S:47_ ZU.>>L*WWO?;:IW3A MSX3M]25]DN&|> ^7KGOF[1OCOH7|87) [[RU<]4Z,? N I MG>QVS[OQCP_ ZPW>_ ^>S_ /E'\$W_ ;E1HFI|=^]?\$/TOJ_ W ON=[\ ?!U#HGA M"+#^,@_]TN^ ^S(_ VJ_ ')#7 C_ "2T?(M]_ KZBO[,/#4HJ0!9_ !/!"S4\$ " M11!T_ U|J T.)Q*0H6+ "_ Q[P UN0*)YO!&4P>B#? T0\$ "5Q\$ "F1;,*/X_ 8P M\$P]]+JY0\$B-Q\$2LQ%/(LQRN\$9EP+SZQ\$U.1J4)0%VQ:{"OWS11"]7),U3Q M%O]PMEYQ%ZD&(\S.%U6N%\$T1^3P#G\$'1\$V^0%Y61;:#OJO^49Q;:LJ6|1J#AOQL2AB'4? U4PQBK,1QU#1O),6=HT1F5YQRC4?^ 0QQ7L>+*,1YA MYOKH\$1@9CAN[40&%XQC?4>2\$-^&Y.[@21VO3AVA M<8:0@/]\$*LA -C%DLDB SLB(%DB/Y#W?"T45>,)Q<#|_ S<;R0PR,K,EDTLB,W M|B5=,B;%L15A|R8S1""Q20_]Y0B4B>QZSED4B7[2UAB3RB#B\$B9;,BF-|MI: M1RD/TC^0\$LV4"1\$|L1X+Z.A,|B13ZCN\$,BI?4EB4TBN/="=S6L2>!:.#S:T@W_ ?T4MEW(O);(OS? +B2.T4P'Q,R),O(S.M0J!DS5% M!11\$ SE4YB(G1+J)'S'^4U2(4.I^1%G4/S<.0\$24U""%(DUT1&13XW#30NG4\$(.O M2(W4| J\$3:6+5-[T3ZL43:M4<0(5_ %*C4*0D[X4E.322Z&30@_ 5T#Y%4"F5 M3Q\$U1!/'4HJ- "IU".7TW<(C3_ 5T0BZUSSPE4C4U55%U+P^G5)>J-)K45?MT MDB!R]J7"5\$?/46&4WRA\$5D%14U355SM56- O2<(+5Y#YC5>=MDO_ LM\$*;J3;3 M0DAK0E2/=*\$&-0PU)4F)55FO]5A#5X(@EIBUIY M]2IODT+ _O)2+V_ %=F A=5LO)611=F% 'JOL !V0YHV!UEKH6:6. '3!&9C[8T M]ESM1T6(U5)R%F>#-FJ=[F|4=C.T]6D!4Y&.KR8:4&9G5A|YI&D? 96>AMFS) M5N_ |9F0U0VH]]6'GB&@UD/J|[[?@MF|_ FZE%NO51S!9K^99MK5&IRE8SSE;>_ M%FEEZU1"G77E> 3S"NMK:78F-550]]9O*7=R9W5O=A8S^M93\$|EN6XD+Y[9Q MDW9+7>1:'65S!|=R4S>V^\$9G-7=U!T]KTV],NK9Q'? =Q(1=0'05V4;=W5=

?=W?W=O@G9XIY=U%TFD@7-|)S;?4GCM;XF=-N981/ M&25]_ ?=]4U=OHG8PT'?EF@PYW<)Y7;S_ &M| <9=#V/1|"WB"U1=UV=>"!>_ -_ MO|N(3C2!|Y=C_ RN0(7?B>)]L7LF@D@A>E@&@%8@VT6;P9X,%0XLXA(LW3&>UGV MA@]W3@OI#OUQJ!Q80CW1|ZT?V.XB%F84O/F;-W7B!INTAX36@TNXP;@V4=.0 M? JT8C(0X2J.7B2GXB/G7A2>7,+@8@7?H(CO"% M%1=GBAU4(>6<\$2[?8B[MX MA8<8;Y08> ^6X@VU(4L_X@|T) [:*T>B"A*]XA,PP1I[T=,Y.),8@|6XD9'UA7;+DOV8 M@C@YB@MY@|J1A(#\$3/66E.=XE^GSD<,X,WCY1VE(/#DB'V.YD[%2/_ *%%" MN92=V2A/V76!F8[WV--<698W+>)9? N?9JN7QJN46#1\$R=5I?)697?T9J&'Q\$81]&#WV9PI^@_ 1N6]/MHMIR-P^XB0_.2L;41.)9\$?G|661MD7*'= <^ J\$ _CCP*.J'=B*%QNJ!' ^99OU%,@>J*!&J7M#XS3 MN3- ^.G!|=2%TM.9.Q.7'EV64_ FN66KB=SNA")1\$E'):A3NJ+3S8Y1 ^63ON(5H M=*D)>=R.N:S92Z&K6J?9FJ&+)\$? =]F:UFJO_ MYJ8[0:2DU5M6|BDL]=M?(\ M\$I'J;[I(^+HR7X6N\$7NN6]FKI3DT"MM'63GH0_ *,LPZPT=JZU+JM-7NM7? NIH0T]Q,M.-9&S-WMIK_ I @R:L M]XBW1R-57^@ _)_ NRB4JV:]J0;_ JV;7NYZ<=('A1H\%J/HANUW_ 9E,7:XS=.X MJTRPD7NYB|1\$?<:W|TB|2R-(K5NX.YJX&2R;J8UY,YNXYN9Y&J|(.5GIAN/ M[MLT=)N=PQ SP1.9J<:.)M=XSO!?' JM#91GR)N.'GP:L?&#?|D MU)O8M/M%WUN^%;S#_ YL[MP,TY&]C]D9<-7RSC!W0PO,76J+NVF9P^7;N4\$4 M9R)'S9DH|C|+|2BV2B+Q0)%H; MMEL6P)V5Q=L8B!&.:9&ZK<_ /BAY[Y*"<6M>&|U'/SSX'\TE5= MP3T|/6%&TK&K|] (O|< M5SVPG!9WO=DU6|Z]TV5D?8RF_ ;G#E M_ ==GDV7,78P2?KB,\$]*_ %A5Q-: @G> IGM47,COM_ :O#)0H])=]OJR5)@K+9 MM2X\$+F;VILK/N7E_ 9NO.CQ59N%E13@3!>9=JR GEK6;VM1SGMVI/"XDNTF> M;.55GM?#?35/QN_ 9<|-'4^07K2N]EO[W-^AS\$#0>R5T?>B%/NOG>46"|]@E MAN;'^_ 7_ 5!.Q#RY3[_8>C5:5;XL2TONWG?4C\$O63_ FOY01)M+YKZR[C+DI7ZB MSN(!/0/K = MX_ SBC9YDR)Y/1)N_ JN3P^U>2992:T]]L(7W4=9|R>=Z6=P(* MUU|@|3_ P+1WNKQ|,-?YT21M"N[RQ#QOR]T.5^W S26+OS?IBN>_ O.[V*Q|N M95YD&|,.\$I^!PYG<76(5_ ^D#40R0YZ-MS[YP-#KB_ F3;/_ YM1SW6U-D[GY+ M2I|#9Z3Z%9F1I|. (BY|XC|_ 6MPPG/O\$E/!_ ZO3T",CW|#SYD=M]*ZOK12Q?X MU|]/[TP.EV2+W1?VUVYW4+_ R 0*7P(\$\$"QH|B#!APA,, "3 |X;#APX@0)UJ4 MB+%B1HH*.WK|B.O"A0@C_ TN2/&DR):?? MU;%RX9>?:K8M7;EZZ>I>V_ 0LX<,>^? O?)7R8K^#%C|L| M5ILX|E|)B"=;YO@X|V(4AB]WK@SZR1"? @F:)%Z!_ %HKHE4@-^N*ABM+*.1U#N5H MI896)&E@EB9J:96<7LK56A+2B&|OI4ZH.FOH3U]]JZV>L%\FRZ:&9NVMGEK MKIE*.JN|N_ X*K&:?.#KMBL,8J- !2QO8+Z*+/_ L'6N>LL|_ W@EMM?Q)BVV1UE*7 M|:]#|D?IM.V)6:Y78[YI.GIGENN8|TF1|JN|N8Z|TEQ- F=OOB|)N6V2S1+9 M;|_ "^ ^3MOW - *O!!2|LKL\$(\W.8NODNCS#8_ 3+/'?=U<|V5.!U_ ^VTWIZ=V'=]BYT* M^:J1R|9JA*|2|OGEER|F|W9F_ W]>-IMQCD[X=HFG5WKJ0#.NN%&JOIWZZ:(; MCN#K|;&.N^VZ=S1[|:]W3ON3IT8?&

<#...;UU\IKI37SYH;:=+7F@3T BO6F/ M?GWV(^TN;/%Y<@^?+1" YTWON.OO SEL\^DZSS [YZFND]/B|\$^ ^:8ZA
MS' _LEP(XK?P8<(9P0AO:\$*BV'.+P31Y< M"P9=U\,@MN6'2Q(B6TY(0B(J,8..7"*GC*BZ)(.09E*.8(LL"))]:>Y5EN-B
MY;Z8.?|OAM\$U,"P4?PB(QC99[X;:TZ&)H%@(5).H%CG2TBAS 5<>K5!&+=W2B M18X'OSYB+
(^\$VZ/0*^@9"0?:MBH8.2W1:N#P62M*%Z)+5T%"4OK*MT8UL["OG
MW<@O0B)D1<12GMU\$AEG1(JJ>2C* UX@OBUTD^KG!LLI :P5\8N;Z1DRG3^
M\|Q@E.SB2R.C62G%OML(UOK.5.G.C.:JDE^*2YC.IB4U=|C)\V9R2->MW M2 +U2YOO.R\$Y,3(V2D92G9!LYV^F\$RXO
C)F:S7|I?I27R"LXD9&B/5.XSV9B=).M0C%G7(2J.)T/6|E"!FVA.6SH|W=WT6\8:EQ%WJ|AJ
MX719.!HJ1+JSSJ2ZDYV3M(T0DQFBD^8SI9^4TSZMVK:9(F2)\|0J(6VZ'J^" M=:Q&:=SKR-J>8WGK@4
JE+*VJRNH@BAY1&F7>^*.B-"M:1NHJH^L>?5@G0S ML*)L:^U>6E.XHA6B.2V=81-T+.&%3/|&#W-5C?70C6
Z0J9O5:E-5:\$2^UG^T M5?5K|JOZ-JR|UJJ\$=4LV6UO^Q0IGL*E|&57-KC:4NFM4|2=:CF4*<.*K/ ME.\8-8II*QWX!DU
'=|B?+;*6 M|L| OJWNM@5L).?W,R7)G3%0." M=- 3B1&D.V9NFYNKW.8B6;I*-O&25?M?)P?
VM53VH)GS@N4 "WK..4O:H.." M8PX#|I#?|2..5|XWU":>8M*^14MDWHA8=#9DQHN|J;-9YVHX%EV%I;^VH5|3+
_5-%V^ZTID>-V|F7*). M&|O.J!VUN|VM55.S6X&Y1B0\$TM:B|U9@P0GPU7YO>^0.V|C'\$OUCMY\$< M4,3|^/
_SFL8D7OFEJYYL(XG#|I|VN+(QKC/XS8"=E=>|/6?13Z/7CMZPLL2|7G\$V7CSLA! UOI===O Q'8IV M;
|SUBGF08+SPMW<<- 7/1@1#>O*6|GU|=^|0.. M*-D3SSVW|J#Q?)S*"<*>=D)3/..C.X+4| |Z1]-#T.-
Y)0TG>:\WV27,>7 MZHT|>-9+7^P!W2|L=2=Y/^<>;L !/F3'27NO-'W'X S EZ%D MWV.. TU+K| M/1SE"8(\,|Z?
1|7E"A7 |UO' @|G#=#|8GQU,GJ>|W&?9X.D-T-ET/MWU^VH..T"i40>J#H%6#ZX M9X(1=G!UEX T9H
M:"0|84Q02#0P>%2/X815F\$6"0FF"(H'+X'J%'V9(' MACU"J:(B)DVO9X2%|!(+|UT18N#.\\$H=(2MW.(7O97U@
M^'Z'>#):A&|T|X-@MX:L9TU%^(:\$@X2Q|X?^ 85T@X57AVV7^&Q4J&5=AH4+ MM(0203?R-BAC*/^&|JA"7'>&T?>
(L4A|T:1-DPB'14=OI5@6D:>+ P:">9AA
MVE:*@*&++B4I|18I.GB#RZB,S=A)V@B*X5=AW|B+;&&.5|8H4|8K8>B.RJ).""|6- M5DA%Z6@1?/B-
P\$A|@VE7B\$GB@>MB1WO0>2W?AVJ<.)2K.16K&%2">0B B/(EF2EV>N#AYM|J:/HZA'NIB)&&91*>G D#CX
M9E<9>L^X=|RT:X AC3PIEJU76+4(E"TYE%FX4 JI:F<%=5\$HCB?)@'BCA&I) M%6=9A^XD| RDZP(CRW1&G-2-
<3BE6%)F*MG2I)8EB,TD/QHER|GB2*7E\$=) MD*R&.&JYAT!|E).J1=8"D?#?'19:V'W.9*"-.SD6A8F+)XF#^4F(9FEX|IF46Y
M.^9(E7KBD8.BE+.4F87SA&KEAM5"D|^Y=VHB/H7&%OERFL?)AE^U3:OY4(OI M6|TXAV>YCLXID-
%6.HTY"8"@T*%F)R9@|^)E37(EQ))JWS% :G,@98\$)|I9&EY<-6C'OB8 1.IL>E&|.6)|P>9|1Y)3MHZ%HZ9^Z|#
"&|J#*4T#F MXSZ#J:.)&DIOQ* NNG06REZ/ET>2*97SR9""^S:J1"YB8+ *3#BF97A*:0L M|9?%\$1T,-*
:\$81>:IQHJZ).VG8W6DA2FIQ29IOB9<4&D5<A J:HS@|Y-! M,J1|6::|9# MBC BZG!C:AR/(9I-
D ^3BKJ|H02/CAJG>%|9|1EHEWBG=XAR>FHI*RD0 "F= MO/BF&S.>P3IL-
DE!AY,J|HJ|@0M2DKAHP#ZIR(ZE@=GIPF'J*EQJ1O=BAM#(P MIVJL-P.>84JH?EDV*D-
"C(&L"5IEK125S\$J2L"HW=|J)L48G,+HG|J4V4J4 M#4\$QO^HT23.H385|TE6J|@H%\$CG&NZ=E#!UE|I|
I^UOI|V%EO3#FM#CN=%)NA MG?J:|=.=/-LI%JHN6\$VI"A"!GNPZBF"R|FPUF^O&BNK^==J3|R|R|JG0|F/
M6&IR9*DTP:*8N"U*J8Z3A3|HHDSEJM5 H ^*K MH0ZZL42C)7&FLS6IM2-&C".+D):F*B&LD9|JY0:J2ZG:(>6)#\$+LS-
K=E+; MEE1\$3>M:.*^&SPKL 0Z1(|@:+V!+F\$3:2&E*MI%9;|F(M/WTLI-FL16ZN!\\$
MM|WZC|I*-21#HG:.\$A|KJ\$5S/RSCMV\$9G12NJC:O:O:NB/W ML|B4.C87O:0|0WM;7N5OO3LI2X&|O:Y:N/#IB73K _|
<2+S'>Z7%|WCY|F|= MB;.E\$Y%92Z:N6Q:.2U3Q:.\863Z!>K '6+|AK8K1|JOB>|VZ|XT2L"WI;^&
M8SL#RL#2^TYK|2|\\$<'T).3L6<\$!#.#.:8Y|1IF9=;B..|V:%)C-C>@.C@* M?+.CZL Q1" M7(V,":HQI):V"KP?
G<+DR,%0|"GC&YOG>TNO^D|J|XS4H|4Q MH2E,B)(C)|JOB4^R|O3N\,R|TK%KX5)0/(LB/^)PP;.B\$&?CE/ !I:!
<+S&%;O*Z8JQ((HW0*PZ|Z7)P^:GRR\$ M>ZJ|HURKN\$K#1?O2- PB5HOFB#Q|/6P MKK5H^F>S,??O4N)S+I:.PXV+
MI-S*B:R?'9=)0C>.)?>REK|NXPXL L^|(O)M7PKMRS-0T@XDG|BU|S+D.R> M\$-MQ:SQ7OCS3#NIR.O H4Q*9OC.
TT3|S.D#@X (H^RBS/>9/#O-B?0)?- MJIR ^"N4L^K/N>-.YMS,"ZS.'YU=T7S0TE?)|M/0?+\$,CYS1X|S2M#0S^CR1
M5|QRDRQ|9MR|Y0/2.>T2>C72)!W+C7K2>7SS)MFS#MID>-6VEYT^RC MTVUM\$E9|U>_ VT^J|U54WU|
:UGG=TM=&<.%LO\$QM3=6.UA0U61SM0&Z-V#P= MUUBMJ)=RW!=VD|6HR:|VI#M
MR#8#SY2MW+FMK8RCV:J+V1H9V|^|QA_XV0X4VJ%M/8H=W')RV|KUW7%GR<7|MOX"|.0H|W @+>'Y+6#>B|
<./LS|/8L?+N H|J\$SDM*. M|M:A=XZWMRHYMATU.(FA7|I|^|C:.'>O5I-7H8"4|4TSD@D?N XCN4M7>4=
MKL:F'6|9#IOS#=#2\$=.1>O-TB#>.*NG0K3N778N.6#>8Y#M:F|QC>")!>> M=F!%GD?
V34".2#IH|K|0'@&\$:NBH+>5|WN8CSN5O%>>/GKQ:[N6\$:^+."^":
M/>:B5.:|O.1|OJ2)S.:+GA|I:O^>0|IZ^W<=2ZSJLZ!(&Z*1A?0M>3G./H
M;=3IBGKHX/WDN XPKUO|HL|DP|J0N|JIDZ1?2WLK)SL>.|J|S:CHC3K^Y7D M/"3HGH|H1ZOAP.|FK,Y:QE|L'E|@/I
|X\$A|L3VE%O*FYYSTUYQMYZ>N5|A MNZ|K&Q@PL|JSM"U+;T.+M^X|CC+|L.OSO8T?LCM1=SVY*T0Y5@%?MUIY5
(|N M|)|M=|Z|I|OLAWN|SE&%18%;^AK/KP|X3P+Q^K%AGE-|F%0:NB|IA|A|O M|_|I^F|O\$!|?2MVL%& SBHSLE2|/#
1|006|4C.K?TJ|3NRC'RG|2T9Q(8#\$ O MH|OH,J 'Z1^BAPO|7I|I?R^Y|D.|BU>|*^HY#9"4(D*EBKOY"Z
M|FA |MB>Z4XO=>G.FP- |S^?|Q(+YZE|XM NF P>ZP\$5|O+R|?KBT)W=%DI M|=S:|X?^U G5.O|X O2ZDN|8?
|.EY|U46Z|4UEV)|FGX|OANO&NODV;O M*1?Z"R?|A7>=!^O^#./|V6K|J|\$?X/ZN|Y=JY6XZ|SX*N^U?4'|/6C|(^=3
M)952^(:?|D3|ZU?H&|>G9#O^"!>|5UMGUC|@:D/1&).URM5R|?%?| (=+ 3
M7RBZA|9/_JA |BW ^9'BZX&C %7S^M.O^|:|^Y ^V+ F@G |_=7|^DQ-". M| M|!1 7|(@@4&&&@P8.&"R9DN-
AP@NX)\$ZD6-'B18P9-6X|0>#|\$1X|@W8< M&9*D2)0G59HDL-'ERXH(9ZT"=|G3Z!|A>)*R;+DT:|(5RHU
MFM3IB:~1I4ZE6M7|5:Q9M6|5VG3I4Z|AF8X%2 ;KV;! 6?5OA|M !&T(D M+ORA|9H+>2*L#1.V:=#+=2ZH29VF|?
^9V&5J1|C=H/(<(X+\$W|YU:| FDY-6O M9| >O4 3Z,W'= O>OL7G| 7GYR^ / W|_!0P^|)!^I^WXZ<\$#\$2TLP- 8+
ME)"L|RLD:|&|XP0P|DL|)"H#4,|Z4,2:~/MO-Y05#%%%HGS;3CD8H1OOIX2
MY!"|Z*33<4<>>V2N1^UN%+|I(LT|LC|.O02+20K&U)I64.DHJH;1RR2NG MU.O)B:3\$|LN6N+RL2C#)#%-:
\$.TDPVU|0K32"|I |LJE:|4|=?GOQN|GY M|+XAF12SL<(-)2SLOQY%*|Z1J|K+M'MZNN3@7+))23#|5|"(W+35PT|4& M:-
|30SLME=3 44|5-46=71B2"F6U.+N(C6(6X! %?ACD-?=>^20U=3WY|T3|GADE%8RHUW598 AI|!O&UN> M@::Z:M%
<3AEKEZC6^FN=50X:.. P%9O|D.|VEVOWU":..6G9ONIM |SD1I)H M@XM&>. ^#HUZNUX>=MDGBB@N V|"..?
Y.X|4W!A8%NFNU>W*KQZ:5O>.:IM #V M|/\$ 6O?@?61O:1/#8|Q|Q>%^O'/YY3 |NZ&Y|XC|?L?'OS+>0^ +?>?>46
M/3>5:G|5J#(!KA FC607ML|B@3?0|3R93|W&SR:L|+G./4*UWJ^6)"14K
MR"%0)19DH9@|V* CO5|)+.2AOV3(*I#=#/!"-R*"G7HM1H^%\$%\$! Y.&B^ M0"7-A#Q23|K8@S_Z0=%^B:L?<
X:1HQ6>.)3HBQ(V(7+>3#-F4/C&OR8AEC-49+ M*9""5C)C4+:X1N?1<(TC:B-
K.\$BP|QVO:TJ.FGI.Y9XE|O)OFH+C40901T3Z M<8Y2|MXB4Y5(2'+IA RQ'AHE%,F-3-*136-A(2F#R<^@+X|R|J
@KW4A.=DG M?EB.(A6O^#Y6RB|3+P1E+;7GR32*49,+LF4O*V1)!H(F""RY41\$-4OA+;ZY39A+ 7&
ZN0+>42)MFML|91,+)|L+QY5*@L"3H*B<%PC:4Z%# M,2\$Z4YB|C*>|&5< T6H0H!U"HIREL^1.G)/JS:1R: M'3^W6:
<4.E.D,|4|1\$TCOHKVVY TY>E5;|JS"(T0OK%#%#%7U!|-|M1.)N7C M|ESZ-
&@E|DFMI.H4|SI0@V:U1VC:J%?|2A2C"DE|QPSK#K|Z5|J#D=|J5*M4 M:UE6N*K-@.Y\$|U!>E>|4?I4GM02E)
(|V:\$.DX8K2M?|J9 L65285E:\$8. M|YEY/G8NH%1L6SU70#0V|B=>=I3 ^NW6KY2JZ*M8D\$KAB89:G.BEAU- V)9
MNU:5|O:U:OW8:|T4R9A*MK(G|U|J"8 L2SDH3I9|J|J%8C65P3B|FKOU6H;AW3

M6Z%>DKF.=6Y@(AM= T"RNK;J8R/L.EV=)"/R\$U?:\$L[6E>F]ZJFE4F^" O> M='(7.? Z3+W3@>J;Z%H:MN^T0(K&;7I'A-+/WQ8AP|TC>?AX7P<(|4E%#2N!B M;E=<| 7P?'"<4PGWY;H5YF(..R3Y-O. EUA*KYV4Q:5W<8&"2 MN)D?E@MF,WP8&<^4QA2ZZ(V=XF\$0|JA7Y=Q?CBN"5 &>&4X,>^2&6:D81K9 MESYN\$F:#S\$XI- > 6/X8E=-2OBM|&6#'(ROWLO\LD9D0U\DI!N5ZT>OF%JO7 MJNX#DE/' -8P6QBZ0M|+G=)'9R+U>,NM|:*8MS1H,NW4=>Y4M)3SN>;RMAG2 MU"K1#? T,2D.O!F9KO&E(XSHFP85T*\$C(J>M.O%0?TEV|;STI#|+2NRLV,5R MEG5Z2<113V-RU"B1X* [ADFNBFABH|@MXU\$5,MW8KD|MBP11TM 2Q<5 <1D|'N MTv7C) [0(VV6Y3|K&9JEU#2LX8S MO>>,U2|: ^MO^5:=@+-AOC^V:W|+>KZ'-K>U.:P3@|4\$=JUL-[W@':|X1W|F# M="AP1")\F0A\$.:J/' <7.ZA0N? S [G=K+H%:1Z#4>9:R?VH!;3TE4P@X@RCG.-G|^K= YWW'Q.:|'2TN"S'A6RK " *K|TQ-F>X\$0^OB8KK:G?N_CU M91K^+P^V?/P;T.^:YC"FG|354BOWP.^E^F2 ^#\$WR|W-|,^.TR|=N=Y^/,@ M)EY>.>8?)\$O>(.|5O= M|KIT9WZJJ^=|9%6V|)|%U:;7S|TQ:;AU1-/XMUG M WSZB@GY|C7MW>\$3?V|&OPO:BLKN9R|?XE"W|^O=/Q- "C7ZQB: ^#.? ?OO' MUBOH|^+O@TYP7?(^S% + 80LKG\$W8%. |6L^R2,|9: D^2NU D0Y&GK ^CN+ MW^JSCYO |P. [<|L> &.,#CR\RHDO:.'!|>0=3|J V'N YL"N"*0 #0V #.) MOHH, (@=%|S"FS\$:2^Q0C|JZF|!\$Q|J&& OWL2NXM!'O| (+I U<"O J*^ M#^P^0%LUI, +|0D K*DI;#/'(VP^%HRSN..V8 K|I3|'P G,62H4F&.;E|JK/74(|8HTBIC!^+|*BK\$D* (TF!+Z":)U;&|K>\$Z: +6TJFK+A:RX|G%)R(FTFUPTIC \$G*,LEW\$|H'VC-@ M|\$H!|=,>R5(HB&4O4G! <89,NVS(F;0:6F,I.7+&J!'|. |L:|@R5V1,N(D<5 M\$CZ-Y\$QO3\$K#|, X&4V3N,I@N4?%7,P:>9"/W,S9H#BZ'*/S, <1A">NW,M9 M^B O&1.?%.D6B59?S.J43.Y&3,J|J2(G|U:;2AZ,3-*VRFH|Q.G.F9 MK8LAO|08X 06O0Q|.NE/PB- /Z..X|Y2Z@YPAVHC*:US0PM*&YWE/ZA2R/Z// MW.PIXQE+Q S+;:@%0L^PFS?3 E\$Q^C.&4|M/PU=4E UU.0K047=T%TEI%5E5?#, M4"UUU>0\$4A\$|I#735++|U4|51YKRU5XM,JOI4UO15O>"U\$5UU'&QTC155M:L M'<=|HLB\$S,/YT\N25D'=/J^R5E3=1J\$.UBRU5 &D4H(\$UQOE37)=3,|A|01Q M.FC=%W>=UMN,5WD- U62U&6X%E8#1>N/<2D55BB'=KMV3 7 M!5%|A9/Y/#D|U.P3Q10G;5L%%"A\$(E):5: V9)^YU567|2FPQ=OHV=? (M166 M:; "91;|A*|M>--QE?5OD HW >5R\$C4 FFES5+5V|4K I+!'JEC9D=U@ 370 M=;|:2|R/G=7&:=R>-- VN+47P6MVP51E@=MQR=SLG%.@:C:|5A.'VX MC1:@:..(X7#NR7>2|G6NG7:H(4Q':6OS14=Z|51BF- !1+K:6|J4WW^V4Z|U! MLF6N|:U?#|G.?74PD3:D+1@FF5:ED2NW14/T6W?Q5V<@L4F!99? M6LXDWA?|0""M@!|ZM&? 7A&F7@?&M:;NU<:/DI M&|ZF#M:8MWUBC!EA=^%A(#OAU.5>+38)R \$ Y/7M,Q|YSTC)B: @5YU> M? H(0|:3B.I+@Z=IB%<9 O^Q:T#/B;UE:."MC+3KC>#0E*?93|^&X3+DQ5AU M8Q/^8C^#63GNS |5Y'N%9- I3X|U\$8LR=+30N5S56J<|08|Y Y'W\$8V #XCD^ M29TC8AH6Y2X|UKQ4VPRVW3|.GT!NOS:;95GF7#W^DJT JNN =M\$%W6+E3&MB VM1Y6Y26>YC,LY@W48S/NMEBV M%EL&V4KMHA#FW3E#X,6*9G.\$XEPC9:3:Y3#N3EXT71\$|)T10R^NB.F@*QD>#=L|P6F@Z MT>FM0%5EQC- N'BSYRK(=J>C=Y<1Q9F.!F>E6 FA"(E2+MJ3)>F(=FJM)3O) M|=|B9FDC"QLBH|BB:XNDT4>NY"6IP.L7:K:ZNS@FC5E=; M>^F,)BA>:;:"QUC63? L^SKL^OI6J8^6N*^XN.9RN>X#KLHE 7EFL24UORSNNLPFC3+ARZVVL|F^R|S\$S85HK8 M3HG95HG:/DW9SFW: |K@2OFR=|=X3N.V1\$.Z/|. |@UFW;1F|JU?Y|%;>.4*P;\$I Q^/T(\$%^7B*1Q'=|QRO9PYF)*^GXRUIY\$'B|RIC8* MGJ0Z(U|R)D=2*OOO%|?KTA;AQ^93UABZ|L|Lr+=|R+N_R47|RV.IG%P|I#*LXY M+S|S-\$|S-5|SM|J|."IP D<0U- K|S/|S/=|S..)D&6VLAO \$|SUD MC%CD/ MN85R=BE |2R:Y W D\$|4=X, >(1/^LM.GORPVM"K)UU2(6?>(|O>|(NOR9VS M|69BWW8'^"%%I>RJD|6 >|)(O>9, >9O#ZF; .L+FR(QX7:4CWF9GWF:GR|= MRW8X W=64D)H3A":Z6:#WJA'WJB%RE*KL9:(T-R2:I*JG?WJHC HWMF2D MUGFKIQBE|I? VB"6I|WJO WJPOT^4)B(%5J.DLAZ#WNU7WNV; M2U>H#+ >. MSWK==%:8'3K5Z @@TK=BS9LF:/HDVK=BW:MF|?PHTK=R|=NG:OXLVK=R ?OG|O'A6* M5# #AHH;- %PZ,>+ BQCW *FRZ0.KD|)6A7GZ:V>EFR90 0VX:87+HTJ9/H L MK7HUZ|:N7|..+7LV|=JV; ^/K3NLX|2'>S/^+=PW|>#%>X>^JGPY|^6|339| M+GTZ|>K6KV|KGT|J|^>OX./+WZ|P.'&SP-|:U| |?7N?^+% -GR?GT|JO' M2C|B@OW^ P,8H(# \$EB@@0A!"R- Z&%0|G5G(8: M>@ MAQ^"&*(Y)8HHDGHIBBBBO21J|\$%<+XHHPTNGAA4E|U-E|FNW(68^>T<>B MD\$,26:211R*9I))+,MFDDUO96&.,4LX8I953TI05AUMR"=637X(9IACDEFF MF6>BF::: (V'99I5N4AGGE<)|I!61 ^/.*YYT^YAG P9I AJHH(,26|BAAR*: M*%P#R GGG(V^&6FC6G99Z8:*8I|IIMRVJFGGX(:H"0DQ|HJ8ZB.EB=>K+* MYYYVM@|KCZ+26|NMM^*:JZZ| |MKK0J=*FRIJ0Y| J66(GN5K|LRVZRSST(: MK.33@D>LL- =:F^UPOF:5H|< ZMBGK+)>26ZZYYZ*:KKKKL MON1<%J6ZR|V ZW M:K+W1N6NOOORVZ^ P(<<)|HQ\$OOO 6C:N^WXH|:L.OZBBPO!-37+ '%%V.< ML6P(P|OQP1X392^^(VMKK?327:=(M|OSTUVWW7= _Q':6>CNZUN.)- J|WXWAZ| 3:BU->N>678YZYN7ROW?FD2@MN|^ .|Z>YZ:>C MGKKJJ |L.>N'Q:YY|VR7KOMM^>N^X+OOXX|(+Y';KP7G>UN "(Y^\\LO' M|KOOSQLE^^S*E^|)=CG|WV8GD.?? >|^0VXZ:..|GVYZ.?OOKKLW|0|^ # M& |T&K9?O WwXY| ZMX|:ZW|79..>-'1'P\$+;. # (G!L ?M>Q XW/^HE,((2 MGA@!2MH,08N4\$KA*Y #0F?!#X(PA"(<(:OPR+).?!"5"\$A"UOHPA?"|)%#P MRZ!*4LA! -HGACK<(0| |Z..DF7"&|\$BA"@F"%J(1YH=*7"(3F^A\$N 0OBL\$3 M8 = 9);W\$.R)6MPB%|OHQ:PA|83^(V(1|B;-WTOC6I<(OO:B LA3NE -Q3? MM|82/S?B,8|ZW&.,Q?@BKY0Q7V!AU*-0P,=#(C*1BI0@#7T"R !"4F=@\$=8B M*VG)2V*2?6)|9"#- Z)5L93*4HAPE*:UWK4?<728X8VP!E#*5|(REK(|W@D(M>11.!O*,Q9HE+WoirU|2.) (XU!|W3@G.8R(SFT94(SFM*IPGOX| MEC:1.Y ZW"< F75=-A:OGG L)T\$+:M"#*NJ!:AEG81#JT(="*)B F@5S2?1 MBV(THQ|5UOPVZM@/C2DGO(F145|TLB-*5FFIU*6^K2E)|41:I GM-2@!TL80N+|4RWUM2PBETL8T.)M|9"-K*2Q>- ^339RV(V MLT|:6P|H(WO.(%557&:|SHK=0-TLO>|OKWC%-Y:WRG2|JB225^N(WO_H% MD2#WZ| _O@_8 LP@0ML8.R)|L *7C"#9:?!D,XPA(NC2,8M;|. (7PSC&,IXQC6L